vs
IMAX（IMAX）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
IMAX的季度营收约是MESA LABORATORIES INC的1.9倍（$125.2M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs 0.5%，领先5.1%），IMAX同比增速更快（35.1% vs 3.6%），IMAX自由现金流更多（$28.0M vs $18.0M），过去两年IMAX的营收复合增速更高（25.8% vs 5.1%）
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
IMAX vs MLAB — 直观对比
营收规模更大
IMAX
是对方的1.9倍
$65.1M
营收增速更快
IMAX
高出31.5%
3.6%
净利率更高
MLAB
高出5.1%
0.5%
自由现金流更多
IMAX
多$9.9M
$18.0M
两年增速更快
IMAX
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $65.1M |
| 净利润 | $637.0K | $3.6M |
| 毛利率 | 57.6% | 64.2% |
| 营业利润率 | 19.3% | 12.2% |
| 净利率 | 0.5% | 5.6% |
| 营收同比 | 35.1% | 3.6% |
| 净利润同比 | -88.0% | 316.6% |
| 每股收益（稀释后） | $0.02 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMAXMLAB
| Q4 25 | $125.2M | $65.1M | ||
| Q3 25 | $106.7M | $60.7M | ||
| Q2 25 | $91.7M | $59.5M | ||
| Q1 25 | $86.7M | $62.1M | ||
| Q4 24 | $92.7M | $62.8M | ||
| Q3 24 | $91.5M | $57.8M | ||
| Q2 24 | $89.0M | $58.2M | ||
| Q1 24 | $79.1M | $58.9M |
净利润IMAXMLAB
| Q4 25 | $637.0K | $3.6M | ||
| Q3 25 | $20.7M | $2.5M | ||
| Q2 25 | $11.3M | $4.7M | ||
| Q1 25 | $2.3M | $-7.1M | ||
| Q4 24 | $5.3M | $-1.7M | ||
| Q3 24 | $13.9M | $3.4M | ||
| Q2 24 | $3.6M | $3.4M | ||
| Q1 24 | $3.3M | $-254.6M |
毛利率IMAXMLAB
| Q4 25 | 57.6% | 64.2% | ||
| Q3 25 | 63.1% | 61.5% | ||
| Q2 25 | 58.5% | 62.0% | ||
| Q1 25 | 61.4% | 61.8% | ||
| Q4 24 | 52.2% | 63.3% | ||
| Q3 24 | 55.8% | 61.3% | ||
| Q2 24 | 49.4% | 64.0% | ||
| Q1 24 | 59.3% | 62.1% |
营业利润率IMAXMLAB
| Q4 25 | 19.3% | 12.2% | ||
| Q3 25 | 27.2% | 7.8% | ||
| Q2 25 | 15.6% | 5.1% | ||
| Q1 25 | 19.3% | 2.4% | ||
| Q4 24 | 10.3% | 9.2% | ||
| Q3 24 | 21.2% | 6.1% | ||
| Q2 24 | 3.2% | 9.6% | ||
| Q1 24 | 15.3% | -460.6% |
净利率IMAXMLAB
| Q4 25 | 0.5% | 5.6% | ||
| Q3 25 | 19.4% | 4.1% | ||
| Q2 25 | 12.3% | 8.0% | ||
| Q1 25 | 2.7% | -11.4% | ||
| Q4 24 | 5.7% | -2.7% | ||
| Q3 24 | 15.2% | 5.9% | ||
| Q2 24 | 4.0% | 5.8% | ||
| Q1 24 | 4.1% | -432.2% |
每股收益（稀释后）IMAXMLAB
| Q4 25 | $0.02 | $0.65 | ||
| Q3 25 | $0.37 | $0.45 | ||
| Q2 25 | $0.20 | $0.85 | ||
| Q1 25 | $0.04 | $-1.30 | ||
| Q4 24 | $0.09 | $-0.31 | ||
| Q3 24 | $0.26 | $0.63 | ||
| Q2 24 | $0.07 | $0.62 | ||
| Q1 24 | $0.06 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.2M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $337.9M | $186.7M |
| 总资产 | $894.0M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资IMAXMLAB
| Q4 25 | $151.2M | $29.0M | ||
| Q3 25 | $143.1M | $20.4M | ||
| Q2 25 | $109.3M | $21.3M | ||
| Q1 25 | $97.1M | $27.3M | ||
| Q4 24 | $100.6M | $27.3M | ||
| Q3 24 | $104.5M | $24.3M | ||
| Q2 24 | $91.6M | $28.5M | ||
| Q1 24 | $81.0M | $28.2M |
总债务IMAXMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益IMAXMLAB
| Q4 25 | $337.9M | $186.7M | ||
| Q3 25 | $349.5M | $178.5M | ||
| Q2 25 | $320.4M | $172.5M | ||
| Q1 25 | $299.5M | $159.8M | ||
| Q4 24 | $299.5M | $155.2M | ||
| Q3 24 | $289.4M | $161.5M | ||
| Q2 24 | $267.2M | $150.7M | ||
| Q1 24 | $258.8M | $145.4M |
总资产IMAXMLAB
| Q4 25 | $894.0M | $434.8M | ||
| Q3 25 | $889.6M | $430.4M | ||
| Q2 25 | $868.6M | $435.7M | ||
| Q1 25 | $848.3M | $433.3M | ||
| Q4 24 | $830.4M | $433.3M | ||
| Q3 24 | $847.6M | $454.1M | ||
| Q2 24 | $827.4M | $440.4M | ||
| Q1 24 | $824.1M | $446.8M |
负债/权益比IMAXMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | $18.0M |
| 自由现金流率自由现金流/营收 | 22.3% | 27.7% |
| 资本支出强度资本支出/营收 | 1.1% | 1.1% |
| 现金转化率经营现金流/净利润 | 46.11× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $118.9M | $37.9M |
8季度趋势，按日历期对齐
经营现金流IMAXMLAB
| Q4 25 | $29.4M | $18.8M | ||
| Q3 25 | $67.5M | $8.2M | ||
| Q2 25 | $23.2M | $1.9M | ||
| Q1 25 | $7.0M | $12.7M | ||
| Q4 24 | $11.5M | $18.1M | ||
| Q3 24 | $35.3M | $5.3M | ||
| Q2 24 | $35.0M | $10.7M | ||
| Q1 24 | $-11.0M | $12.9M |
自由现金流IMAXMLAB
| Q4 25 | $28.0M | $18.0M | ||
| Q3 25 | $64.8M | $7.1M | ||
| Q2 25 | $20.9M | $884.0K | ||
| Q1 25 | $5.3M | $11.9M | ||
| Q4 24 | $6.9M | $17.3M | ||
| Q3 24 | $34.2M | $3.5M | ||
| Q2 24 | $33.5M | $9.9M | ||
| Q1 24 | $-12.1M | $12.3M |
自由现金流率IMAXMLAB
| Q4 25 | 22.3% | 27.7% | ||
| Q3 25 | 60.7% | 11.7% | ||
| Q2 25 | 22.8% | 1.5% | ||
| Q1 25 | 6.1% | 19.2% | ||
| Q4 24 | 7.4% | 27.6% | ||
| Q3 24 | 37.3% | 6.0% | ||
| Q2 24 | 37.6% | 16.9% | ||
| Q1 24 | -15.3% | 21.0% |
资本支出强度IMAXMLAB
| Q4 25 | 1.1% | 1.1% | ||
| Q3 25 | 2.6% | 1.8% | ||
| Q2 25 | 2.6% | 1.7% | ||
| Q1 25 | 1.9% | 1.2% | ||
| Q4 24 | 5.0% | 1.3% | ||
| Q3 24 | 1.2% | 3.1% | ||
| Q2 24 | 1.8% | 1.5% | ||
| Q1 24 | 1.4% | 0.9% |
现金转化率IMAXMLAB
| Q4 25 | 46.11× | 5.17× | ||
| Q3 25 | 3.27× | 3.32× | ||
| Q2 25 | 2.06× | 0.40× | ||
| Q1 25 | 2.99× | — | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | 1.54× | ||
| Q2 24 | 9.78× | 3.17× | ||
| Q1 24 | -3.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
